The prognosis for uterine sarcoma is primarily dependent on the extent of disease at the time of diagnosis. 2 or 3 carcinoma are all significant predictors of metastatic disease at initial surgery. These factors, along with adnexal spread, lymph node metastases, tumor size, peritoneal cytologic findings, and depth of myometrial invasion correlate with progression-free interval. The presence or absence of stromal heterologous elements, the types of such elements, the grade of the stromal components, and the mitotic activity of the stromal components bear no relationship to the presence or absence of metastases at surgical exploration. The type of heterologous sarcoma had no effect on the progression-free interval.
Surgery alone can be curative if the malignancy is contained within the uterus.
The value of pelvic radiation is not established. Current studies consist primarily of Phase II chemotherapy trials for advanced disease. Yet, other nonrandomized trials have reported improved survival following adjuvant chemotherapy with or without radiation therapy. Classifying, staging, and treating uterine sarcomas. Omura GA, Blessing JA, Major F, et al.